Table 2.
Baseline characteristics.
| Placebo (n = 10) | Propranolol (n = 10) | p | |
|---|---|---|---|
| Age—years (mean ± SD) | 51 ± 9 | 57 ± 11 | 0.262 |
| Gender (F,M) | 9:1 | 6:4 | 0.152 |
| Gene mutation (number of participants) |
ACVRL1-8 Endoglin-1 ND-1 |
ACVRL1-5 Endoglin-3 ND-2 |
0.223 |
| ESS | 5.68 ± 1.8 | 6.50 ± 1.84 | 0.323 |
| QOL | 34.75 ± 10.9 | 35.1 ± 6.7 | 0.932 |
| Hemoglobin (g/dL) | 10.7 ± 2.52 | 10.57 ± 2.6 | 0.918 |
| IV iron */IV PC * | 16/3 | 9/7 | 0.739/0.481 |
| Ferritin | 65.4 ± 86.19 | 89.65 ± 212.04 | 0.715 |
| Rhinology grading (number of patients) | 0.601 | ||
| Grade I | 4 | 3 | |
| Grade II | 5 | 5 | |
| Grade III | 1 | 2 | |
| Systolic BP mmHg (mean ± SD) |
110.2 ± 9.6 | 119.3 ± 12.3 | 0.09 |
| Diastolic BP mmHg (mean ± SD) |
63.3 ± 9.2 | 69.0 ± 9.2 | 0.20 |
| HR per minute (mean ± SD) |
76.0 ± 12.9 | 73.9 ± 111.7 | 0.71 |
* Total number of units of IV iron (Ferinject 500 mg)/IV packed cells (PC) in the 2 months prior to screening. ESS, epistaxis severity score; ACVRL1, activin receptor-like 1; ND, not done; QOL, quality of life; IV, intravenous; PC, packed cells; BP, blood pressure; HR, heart rate.